Signaturefd LLC Has $1.11 Million Stock Holdings in GSK plc (NYSE:GSK)

Signaturefd LLC raised its position in shares of GSK plc (NYSE:GSK) by 4.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,913 shares of the pharmaceutical company’s stock after purchasing an additional 1,262 shares during the period. Signaturefd LLC’s holdings in GSK were worth $1,109,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in shares of GSK by 7.7% during the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after buying an additional 1,291,161 shares during the last quarter. Primecap Management Co. CA boosted its position in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 12,058,770 shares of the pharmaceutical company’s stock valued at $437,130,000 after buying an additional 287,000 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of GSK by 5.1% during the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock valued at $292,896,000 after acquiring an additional 389,871 shares in the last quarter. Morgan Stanley grew its holdings in shares of GSK by 2.1% during the third quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock worth $273,744,000 after purchasing an additional 156,480 shares during the last quarter. Finally, Equity Investment Corp grew its holdings in GSK by 2.8% during the 3rd quarter. Equity Investment Corp now owns 3,277,362 shares of the pharmaceutical company’s stock worth $118,804,000 after acquiring an additional 90,579 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the subject of a number of recent analyst reports. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Jefferies Financial Group raised GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Finally, Morgan Stanley initiated coverage on GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

GSK Price Performance

GSK stock opened at $40.60 on Tuesday. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The stock has a market capitalization of $84.14 billion, a PE ratio of 13.49, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. The company’s 50-day moving average is $41.88 and its 200-day moving average is $38.86. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.04). The firm had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. Equities research analysts expect that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were paid a dividend of $0.3564 per share. This represents a $1.43 dividend on an annualized basis and a yield of 3.51%. The ex-dividend date was Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. GSK’s payout ratio is 52.82%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.